CARsgen Therapeutics Presented at the 2017 BIO International Convention

CARsgen Presents Phase I Results of CAR-GPC3 T HCC Trial at ASCO 2017 Annual Meeting

CARsgen Therapeutics Opens CAR T-cell Manufacturing Facility in Shanghai

CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology

CARsgen Completes Series A Financing

CARsgen Therapeutics Completes $30 Million Series B Financing

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion